Taysha Gene Therapies, Inc. is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 73 full-time employees. The company went IPO on 2020-09-24. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The firm is evaluating TSHA-102 in the REVEAL Phase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. The company has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
How did TSHA's recent EPS compare to expectations?
The most recent EPS for Taysha Gene Therapies Inc is $-0.12, beating expectations of $-0.09.
How did Taysha Gene Therapies Inc TSHA's revenue perform in the last quarter?
Taysha Gene Therapies Inc revenue for the last quarter is $-0.12
What is the revenue estimate for Taysha Gene Therapies Inc?
According to 13 of Wall street analyst, the revenue estimate of Taysha Gene Therapies Inc range from $3.99M to $0.0
What's the earning quality score for Taysha Gene Therapies Inc?
Taysha Gene Therapies Inc has a earning quality score of B+/45.58617. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Taysha Gene Therapies Inc report earnings?
Taysha Gene Therapies Inc next earnings report is expected in 2026-08-04
What are Taysha Gene Therapies Inc's expected earnings?
Taysha Gene Therapies Inc expected earnings is $693.6K, according to wall-street analysts.
Did Taysha Gene Therapies Inc beat earnings expectations?
Taysha Gene Therapies Inc recent earnings of $0.0 does not beat expectations.